Outcomes of single dose COVID-19 vaccines: Eight month follow-up of a large cohort in Saudi Arabia

• DOI: 10.1016/j.jiph.2022.04.001
• Publication Date: 2022-04-06T23:29:49Z
• Authors: Naif Khalaf Alharbi; Jaffar A. Al-Tawfiq; Suliman Alghnam; Amal Alwehaibe; Abrar Alasmari; Suliman A. Alsagaby; Faisal Alsubaie; Majid Alshomrani; Fayssal M. Farahat; Mohammad Bosaeed; Ahmad Alharbi; Omar Aldibasi; Abdullah M. Assiri
• Keywords: 2019-20 coronavirus outbreak; Coronavirus Infections

Two vaccines for COVID-19 have been approved and administered in the Kingdom of Saudi Arabia (KSA); Pfizer-BioNtech BNT162b2 AstraZeneca-Oxford AZD1222 vaccines. The purpose this study was to describe real-world data on outcome single dose these a large cohort KSA analyse demographics co-morbidities as risk factors infection post one-dose vaccination. In prospective study, total 18,543 subjects received one either at vaccination centre KSA, were followed up three eight months. Data collected from sources; clinical medical records, adverse events (AEs) self-reporting system, national databases. conducted during pandemic restrictions travel, mobility, social interactions. median age participants 33 years with an average body mass index 27.3. majority males (60.1%). Results showed that 92.17% had no post-vaccination documented 1452 (7.83%). Diabetes mellitus 03), organ transplantation (p = 0.02), obesity < 0.01) associated post-vaccination. Unlike vaccine type, being Saudi, male, or obese occurrence breakthrough infections more than other parameters. AEs included injection site pain, fatigue, fever, myalgia, headache reported by 5.8% subjects. Single protection rate months follow-up cohort. This higher what previously effectiveness studies trials. Obese, contracting post-vaccination, male might interaction public when mobility interactions limited pandemic. Side effects within has